Search This Blog

Wednesday, July 22, 2020

Over half of U.S. companies plan virus contact tracing for employees

More than half of U.S. companies surveyed by benefits company Mercer are starting COVID-19 contact tracing programs in their workplace with employees venturing back to offices even as new cases soar nationally.
Countries such as South Korea have managed to contain the disease in part by tracking down and isolating everyone who has been in contact with an infected person.
But the premature reopening of many states’ economies that led to huge spikes in COVID-19 cases, testing delays, and a shortage of trained contact tracers have stymied tracking efforts in the United States.
The lack of a coordinated federal effort that has left U.S. states to manage all aspects of contact tracing has also contributed to the need for large companies to take matters into their own hands.
Of the more than 300 companies that took part in the survey, 54% are planning to implement a contact tracing program or had already started one, Mercer said.
Among those who responded, the survey found that 42% of companies said they are using existing employees to do contact tracing and 9% are training employees now. In addition, about 4% said they will be hiring more staff and/or a vendor for their contact-tracing efforts, and about 3% plan to use a smart phone app or wearable device to track employee contacts.
“Time is really, really important here given how this virus spreads exponentially,” Mercer health practice co-leader David Zieg said.
Employers are stepping up as U.S. public health agencies struggle to keep up with new cases.

HUNDREDS OF THOUSANDS OF TRACERS NEEDED

COVID-19 has claimed the lives of more than 142,000 Americans, and infections rates, hospitalizations and deaths are all on the rise again in many U.S. states, forcing President Donald Trump on Tuesday to finally acknowledge the crisis could get worse before it improves.
It has been estimated that hundreds of thousands of contact tracers would be needed in the United States to track down those exposed to the virus and garner the kind of results seen in South Korea and elsewhere. NPR surveyed all 50 states in June and found that about 37,000 contact tracers had been hired.
Many states reopened without reaching benchmarks for doing so safely, such as two weeks of declining COVID-19 cases and having adequate contact tracing in place. Long delays in getting back test results has added to the problems.
California, the most populous U.S. state, is averaging more than 9,000 new cases per day and has had to reclose some businesses. It has trained about 3,600 state workers to do contact tracing, about one-third of whom have been deployed with another 300 to be added this week, a California Department of Health spokeswoman said on Wednesday.
In workplace tracing programs, Zieg said, employers should move quickly to interview the potentially infected employee by phone to determine close contacts in the office, notify the other employees about their exposure, and ask them to self-quarantine, even if the employee does not yet have test results.
The employer should also reach out to local public health authorities for more guidance as needed, he said.
U.S. companies closed their workplaces to all but essential staff in March due to the global pandemic.
While most states have since begun reopening businesses, many workers have not yet returned to their offices. For those who have, workplace safety measures include a combination of temperature checks, face covering and social distancing.
Contact tracing combined with other safe workplace practices can reduce workplace transmission by 85%, according to Neal Mills, chief medical officer at healthcare benefits group Aon.
Having contact tracers in place can help bring workers back into the office by reassuring them that all possible safety precautions have been put in place, Mills said.
“They have to have these contact tracing pieces ready to go right now since the public health agencies might not be ready,” Mills said.

California surpasses New York as worst-hit state in coronavirus cases

California on Wednesday overtook New York, the original epicenter of the nation’s outbreak, as the worst-hit state for cases of COVID-19, according to a Reuters tally of county data.
Total cases in the most populous U.S. state climbed above 414,000 with just a handful of California counties reporting 4,700 new cases so far on Wednesday.
New York has recorded by far the most deaths of any U.S. state at over 32,000 with California in fourth place with nearly 8,000 deaths.
If California were a country, it would rank fifth in the world for total COVID-19 cases behind only the United States, Brazil, India and Russia. New York currently has over 412,800 total cases and is adding on average 700 new cases a day in July. In California there is an average of 8,300 new cases a day.
The rapid increase of cases has made it difficult to trace the pathogen’s path through the community through contact tracing, a process of interviewing people who test positive for the virus to find out how they were exposed, and whom they in turn might have exposed, California Secretary of Health and Human Services Mark Ghaly said on Tuesday.
“No one anticipated building a program to contact trace the number of cases we’re seeing here,” Dr. Ghaly said at a news conference, referring to Los Angeles and other counties struggling to trace cases of the disease.
The nation’s top infectious disease expert, Dr. Anthony Fauci, said on CNN Tuesday the main issue with testing is that results often do not come back for days, making it too late to do a proper job of contact tracing.
Since its crush of cases earlier this year, New York state has gotten the virus under control, reporting the fewest hospitalizations in four months on Monday and only two deaths on Tuesday.
About 142,000 Americans have died of COVID-19 – nearly a quarter of the global total.

ROCHE HOLDINGS AG Receives a Buy rating from JP Morgan

In a research note published by Richard Vosser, JP Morgan advises its customers to buy the stock. The target price is unchanged and still at CHF 400.

New coronavirus mutation causes outbreaks to spread more quickly

A new coronavirus mutation has become the most dominant strain of the virus — and is causing outbreaks to spread more quickly across the world, an expert said.
Professor Nick Loman, of the University of Birmingham, who is part of the COVID-19 Genomics Consortium, told BBC Radio 4’s “Today” program that the mutation, known as D614G, is forming clusters more quickly in the UK than the original virus from Wuhan.
“It exists in the spike protein, which is a very important way that the coronavirus can enter human cells, and we have been noticing in the UK and worldwide that this mutation has been increasing in frequency,” Loman said. “This mutation was predicted first by computer modeling to have some impact on the structure of that protein and the ability of the virus to bind and enter cells and then quite recently was shown in laboratory experiments to increase the infectivity of cells.”
Scientists came to the conclusion after analyzing more than 40,000 genomes in the UK, according to Loman.
The new mutation, however, is not believed to cause a greater risk of death or lengthier hospital stays, the Telegraph reported.
Loman called the mutation “the most dominant mutation — it’s about 75 percent of cases.”
“This increase in this mutation is a worldwide phenomenon,” he added. “The original virus out of Wuhan had the D-type, but the G-type has become much more dominant across the world, including the UK.”
However, the strain is not expected to impact the process of finding a vaccine for COVID-19, he added.
He also attempted to alleviate any concerns that the mutation might signal a deadly new phase for the coronavirus.
“It’s a small impact, we think, and we’re not completely confident about that, but we found by testing what happened in the UK that the viruses that contained the G-type of mutation seemed to form clusters of cases faster, which ended up being bigger than viruses with the D-mutation,” the professor said. “We didn’t see any significant association with survival and the length of hospital stays with this mutation — we don’t think this mutation is important in changing virulence. The effect seems to be on transmissibility. ”in the UK that the viruses that contained the G-type of mutation seemed to form clusters of cases faster, which ended up being bigger than viruses with the D-mutation,” the professor said. “We didn’t see any significant association with survival and the length of hospital stays with this mutation — we don’t think this mutation is important in changing virulence. The effect seems to be on transmissibility.”
Dr. Heidi J. Zapata, a Yale Medicine infectious disease specialist and immunologist, also said there’s not enough conclusive evidence to suggest the virus is becoming more infectious or deadly.


Shipments of Sanofi flu vaccine underway

Sanofi Pasteur, Sanofi’s (NASDAQ:SNY) vaccine unit, announces the first shipment of influenza vaccine for the upcoming 2020-2021 season. Shipments will continue through early November.
In anticipation of increased demand, it increased production and market distribution compared to last year.

Genfit bails on elafibranor in NASH

As many expected after announcing negative interim results on May 11, Genfit (NASDAQ:GNFT) has decided to discontinue the Phase 3 RESOLVE-IT study evaluating elafibranor in patients with nonalcoholic steatohepatitis (NASH).
The company’s “new strategy” will focus on developing elafibranor for primary biliary cholangitis (PBC) and growing its NIS4 business in NASH diagnostics.

Pfizer, BioNTech ink deal with U.S. for 600M doses of COVID-19 vaccine

Pfizer (NYSE:PFE) and development partner BioNTech (NASDAQ:BNTX) announce a deal with the U.S. Department of Health and Human Services for up to 600M doses of their COVID-19 vaccine, currently dubbed BNT162 (BNT162b1 and BNT162b2 have Fast Track status).
The feds have placed an initial order of 100M doses for $1.95B ($19.50/dose) and may acquire up to 500M additional doses under the Operation Warp Speed program.
People will receive the vaccine at no cost per the government’s commitment for free access.
The company’s believe that they can make 100M doses by year-end and potentially more than 1.3B doses by the end of 2021.